FDA Approves Cemiplimab-rwlc as First Immunotherapy for Advanced BCC

On February 9, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to cemiplimab-rwlc for patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate and granted accelerated approval to cemiplimab-rwlc for patients with metastatic basal cell carxinoma previously treated with a HHI or for whom a HHI is not appropriate.

Read the FDA announcement.

Read Sanofi and Regeneron's announcements.

Posted 2/10/21